Home Newsfeeds Event Software Company Cvent Explores Sale, WSJ Reports

Event Software Company Cvent Explores Sale, WSJ Reports

https://www.wsj.com/articles/event-software-company-cvent-explores-sale-11675198077?mod=tech_lead_pos11

byBenzinga Newsdesk

February 1, 2023

1 minute read

https://www.wsj.com/articles/event-software-company-cvent-explores-sale-11675198077?mod=tech_lead_pos11

JonesTrading Initiates Coverage On Fusion Pharmaceuticals with Buy Rating, Announces Price Target of $10

By Benzinga Newsdesk

September 7, 5:11 AM

JonesTrading analyst Justin Walsh initiates coverage on Fusion Pharmaceuticals (NASDAQ:FUSN) with a Buy rating and announces Price Target of $10.

FUSN

Goldman Sachs Downgrades Reliance Steel & Aluminum to Neutral, Lowers Price Target to $201

By Benzinga Newsdesk

October 6, 4:55 AM

Goldman Sachs analyst Emily Chieng downgrades Reliance Steel & Aluminum (NYSE:RS) from Buy to Neutral and lowers the price target from $218 to $201.

News

Aptorum Group Updates On The Clinical Validation Of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics

By Benzinga Newsdesk

September 15, 7:07 AM

Aptorum Group Limited (NASDAQ:APM, PARIS:APM) a clinical stage biopharmaceutical company dedicated to tackling unmet medical needs in oncology, autoimmune diseases and infectious diseases, is pleased to announce further

APM

Why Cingulate Shares Are Trading Higher Today

By Vandana Singh

February 24, 9:19 AM

Cingulate Inc (NASDAQ:CING) announced positive topline results from the CTx-1301-003 study assessing the effect of food on the absorption of its…

CING

Event Software Company Cvent Explores Sale, WSJ Reports

Related Posts

JonesTrading Initiates Coverage On Fusion Pharmaceuticals with Buy Rating, Announces Price Target of $10

Goldman Sachs Downgrades Reliance Steel & Aluminum to Neutral, Lowers Price Target to $201

Aptorum Group Updates On The Clinical Validation Of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics

Why Cingulate Shares Are Trading Higher Today